Trial Profile
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Aducanumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational
- Acronyms EMBARK
- Sponsors Biogen
- 13 Apr 2024 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 06 Apr 2024 This study has been completed in Belgium, according to European Clinical Trials Database record.
- 31 Jan 2024 According to a Biogen media release, company will discontinue the development and commercialization of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use.